Estrace Articles
Once-Weekly HRT Patch Approved
16 December 1996
Parke-Davis's Estrostep Approved In USA
21 October 1996
R-PR Posts Profits Climb But Flat Turnover In First Half
5 August 1996
R-PR's Menorest Receives Further Approvals
22 July 1996
Further Applications Filed For Alora Patch
8 July 1996
UK Industry Code of Practice Review
8 July 1996
R-PR And Novo Forge HRT Alliance
20 May 1996
Estreva Launched In France
13 May 1996
USA Approves Estring
6 May 1996
R-PR receive new Menorest approval
22 January 1996
R-PR Starts Fisons R&D Integration; Product Update
4 December 1995
R-PR launches Menorest
4 December 1995
Pharmacia & Upjohn's Estring approvable...
27 November 1995
TheraTech/Solvay Collaborate On New HRT
6 November 1995
R-PR gets Menorest approvals
30 October 1995
Fournier Will Remain Independent Company
23 October 1995
FDA Panel Verdict On Premarin Inconclusive
7 August 1995
Besins Iscovesco launches Oestrodose
5 June 1995
Rhone-Poulenc Rorer has UK approval for Menorest
22 May 1995
Hoechst Roussel"s Oestrogel
15 May 1995
Sanofi Launches New HRT Approach In UK
8 May 1995
Duphar Launch
24 April 1995
Grelan To Distribute TheraTech Patch
24 April 1995
Ciba Reveals Pipeline With Broad Reach
17 April 1995
Zeneca Submits UK Arimidex Application
10 April 1995
Roussel-Uclaf Details Group Pipeline Plans
10 April 1995
FDA Approves New Indication For Lovenox
27 March 1995
Kliofem Available In The UK
20 March 1995
First Launch For Menorest In Holland
20 March 1995
Zoladex Backed By FDA Committee
27 February 1995
1994 Transitional For R-PR With Better Second Half
6 February 1995
Forest/Ethical Deal
30 January 1995
Clinical Results With Zeneca's ICI 182780
16 January 1995
R-PR's Menorest Approved In France
16 January 1995
Roberts Acquires Two New Products
5 December 1994
1st Approval For R-PR, Noven's Menorest
14 November 1994
Estring Launch
14 November 1994
Torii Licenses UK Product
5 September 1994
PHARMOS: AN EYE FOR A PRODUCT TARGET
2 May 1994
NOVEN RECEIVES APPROVABLE LETTER
11 April 1994
B-MS LAUNCH IN USA
28 March 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
CYGNUS TO FILE FOR ALPRAZOLAM PATCH
23 August 1993
RHONE-POULENC: A TRANSFORMATION
16 August 1993
RHONE-POULENC RORER'S FOCUSED R&D PIPELINE
7 June 1993
RECORDATI REFOCUSES; NEW DRUGS OUT SOON
24 May 1993
CIBA'S 1992 HEALTH CARE PROFITS SQUEEZED
5 April 1993
WORLD ENDOCRINE MARKET AND FORECASTS
29 March 1993
RHONE-POULENC RORER SALES $4 BILLION IN 1992
8 February 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
JOHNSON & JOHNSON RECEIVES APPROVAL
21 December 1992
NOVEL TREATMENT FOR BREAST CANCER
2 November 1992
MIFEGYNE EFFECTIVE POSTCOITAL PILL?
12 October 1992
NEW ESTRACE INDICATION
12 October 1992
A PROFILE OF ISRAEL'S AVITEK
6 July 1992
WARNER-LAMBERT EARNINGS FORECAST
29 June 1992
ZOLADEX BEST FOR ENDOMETRIOSIS
15 June 1992
ITALY'S RECORDATI LOOKS FOR EXPANSION
15 June 1992
HORMONE REPLACEMENT THERAPY: US REPORT
8 June 1992
GYNEX PRODUCT AIDS TURNER'S PATIENTS
8 June 1992
ZOLADEX GAINS BREAST CANCER INDICATION IN UK
18 May 1992
RU's DIMETROSE FOR CYCLIC MASTALGIA
3 February 1992
AKZO AFTER 15% of US PILL MARKET
6 January 1992
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
